The Innovative Medicines Initiative (IMI) recently launched its third public–private partnership, ENABLE (European Gram-negative Antibacterial Engine), to tackle the shortage of effective antimicrobial drugs for Gram-negative pathogens.
This is a preview of subscription content, log in via an institution to check access.
References
Boucher H. W. et al. Clin. Infect. Dis. 56, 1685–1694 (2013).
Morel C. M. & Mossialos E. BMJ 340, c2115 (2010).
Laxminarayan R. et al. Lancet Infect. Dis. 13, 1057–1098 (2013).
Rex J. H. et al. Lancet Infect. Dis. 13, 269–275 (2013).
Caliendo A. M. et al. Clin. Infect. Dis. 57, S139–S170 (2013).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
J.H.R. is an employee and shareholder of AstraZeneca Pharmaceuticals. He is a non-executive director of, shareholder of, and consultant to F2G Pharmaceuticals and a consultant to Advent Life Sciences (an investor in F2G Pharmaceuticals).
Rights and permissions
About this article
Cite this article
Rex, J. ND4BB: addressing the antimicrobial resistance crisis. Nat Rev Microbiol 12, 231–232 (2014). https://doi.org/10.1038/nrmicro3245
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrmicro3245
- Springer Nature Limited
This article is cited by
-
Synthetic sideromycins (skepticism and optimism): selective generation of either broad or narrow spectrum Gram-negative antibiotics
BioMetals (2019)
-
Lipophilic teicoplanin pseudoaglycon derivatives are active against vancomycin- and teicoplanin-resistant enterococci
The Journal of Antibiotics (2017)
-
New approaches to antibiotic discovery
Biotechnology Letters (2017)
-
What we may expect from novel antibacterial agents in the pipeline with respect to resistance and pharmacodynamic principles
Journal of Pharmacokinetics and Pharmacodynamics (2017)
-
A bioinspired peptide scaffold with high antibiotic activity and low in vivo toxicity
Scientific Reports (2015)